|Bid||1.0400 x 3000|
|Ask||1.1100 x 800|
|Day's Range||1.0600 - 1.0892|
|52 Week Range||1.0300 - 3.4800|
|Beta (5Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for FBRX
NEW YORK, August 17, 2022--Camac Partners, LLC (together with its affiliates, "Camac" or "we"), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) ("Forte" or the "Company"), today expressed concerns regarding the Company’s sizable trading price discount relative to its cash on hand and the Board of Directors’ (the "Board") decision to conduct a highly dilutive equity capital raise following the emergence of four separate Schedule 13D filers.
DALLAS, August 15, 2022--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced second quarter 2022 results and provided a business update.
We can readily understand why investors are attracted to unprofitable companies. For example, although...